Gamida Cell Ltd.

Ladies and gentlemen, thank you for standing by. Welcome to the Gameta Cells conference call for second quarter 723 financial results. My name is Michelle and I'll be your operator for today's call. Please be advised that this call is being recorded at Gameta Cells request. And now I would like to introduce your host for today's call, Mike Kuskowski of Gameta Cell Corporate Communications. Mike, please go ahead.

Thank you, and good morning, everyone.

Welcome to today's call, during which we will provide an update on the company and review our financial results for the second quarter of 2023. Earlier this morning, we issued a press release summarizing our financial results and providing a business update, which is available on our website at www.gametacell.com. Here with me on our call today are Abby Jenkins, President and Chief Executive Officer, Michelle Corfin, Chief Operating Officer and Chief Commercial Officer, Ronit Simantav, Chief Medical Officer and Chief Scientific Officer, and Terry Coelho, our Chief Financial Officer. Before we begin, I want to remind everyone that during this call, we may make forward-looking statements about our future expectations and plans, including with respect to the product and product candidates, the potentially life-saving or curative therapeutic and commercial potential of GametaCell's product Amasurge, expectations regarding the commercial launch of Amasurge and its potential to capture market share, the company's plans for commercial or strategic partnerships to support the launch of On The Surge, and the company's anticipated financial runway. Our actual results may differ materially from what we project today due to a number of important factors, including those related to clinical, scientific, regulatory, and technical developments, and those inherent in the process of developing and commercializing products and product candidates that are safe and effective for human use as human therapeutics, and in the endeavor of building a business around our product and product candidates as well as those considerations described in the risk factors section of our most recent quarterly report on Form 10-Q and other filings that we may make with the SEC from time to time. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information or future events, except as required by applicable law. Now, I will turn the call over to our President and CEO, Abby Jenkins. Abby?